To obtain further direct experimental evidence supporting these hypotheses, here, we wished to evaluate the effect of SOS1 and/or SOS2 genetic ablation in a mouse model of p210BCR/ABL-driven CML and derived cell lines. The gene discussed is SOS1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.